Engineering and scientific technology company Renishaw has gained Horizon 2020 support to trial a new drug delivery system in the treatment of Parkinson’s disease.
Renishaw’s novel drug delivery system is set to be used in partnership with Herantis Pharma Plc’s drug candidate, cerebral dopamine neurotrophic factor (CDNF) for the treatment of Parkinson’s disease.
The study will be supported by a €6m grant from Horizon 2020.
Neurodegenerative diseases such as Parkinson’s are particularly difficult to target with medication due to the protective role of the blood-brain barrier. Renishaw has developed an innovative system which bypasses the blood-brain barrier, delivering pharmaceuticals directly into the brain tissue. The 18 patients taking part in the trial will have a small port implanted into the skull close to the ear. This will allow clinicians to deliver CDNF to target areas through four tubes that will be carefully placed into the patients’ brains.
Renishaw is one of 11 partners who will be working together to execute the clinical trials. The drug, CDNF, aims to relieve the symptoms of Parkinson’s by protecting and regenerating dopamine producing neurons.
Paul Skinner, operations manager for Renishaw’s Neurological Products Division, said: “We are very pleased to be able to contribute our engineering technology and experience to this important trial.
“Our drug delivery system has shown promising initial results and we look forward to working closely with Herantis and the other partners to achieve the best possible outcomes for the patients.”
Developers hope that CDNF when delivered directly into the brain with Renishaw’s system can help prevent disease progression or treat the motor and non-motor symptoms together.